Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Transformation to pure-play Innovative Medicines company nears completion
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Subscribe To Our Newsletter & Stay Updated
